Skip to content
DataLookout
Menu

NCT05761795

Efficacy of IVMED-85 on Pediatric Myopia

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 8 months later, primary endpoint(s) modified, and 1 more.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment reduced: 216 → 144 participants Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Primary completion pushed from May 2026 to Feb 2029
    • Phase changed: Phase 1/2 → Phase 2
    • Start date: Feb 2024 to Feb 2027
    • Eligibility criteria shortened, about 76 words
    • Study completion pushed from Dec 2026 to Jun 2029
    • Interventions modified
    • Trial arms changed: 7 → 3
    • Secondary endpoints: 6 to 5
    • Study description expanded, about 217 words
  2. Notable Primary completion date: May 2025 to May 2026
    • Start date: May 2023 to Feb 2024
    • Study completion date: Dec 2025 to Dec 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Refractive error change from baseline at Month 12
Timeframe: Baseline compared to month 12

Secondary (5)

Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
Change in optical biometrics
Refractive error at non-final study visits
Sub foveal choroidal thickness
Accommodative amplitude in the spherical equivalent

Arms and interventions

IVMED-85 Low DoseExperimental

Total subjects n=48, IVMED-85 low dose BID for 12 months

IVMED-85 High DoseExperimental

Total subjects n=48, IVMED-85 high dose BID for 12 months

PlaceboPlacebo comparator

Total subjects n=48, placebo BID for 12 months

Drugs: IVMED-85 ophthalmic solution, Low Dose, IVMED-85 ophthalmic solution, High dose, Placebo